2. Fluid Management in Dengue Hemorrhagic Fever

1. 2. Fluid Management in Dengue Hemorrhagic Fever Dengue Expert Advisory Group

2. Dengue Virus Infection Asymptomatic Symptomatic – Undifferentiated Febrile Illness – Dengue Fever – Dengue Hemorrhagic Fever  Non Shock  Shock

3. Dengue Hemorrhagic Fever Febrile Phase Critical phase characterized by plasma leak Convalescent Phase

4. Dengue “Leak” Fever Plasma leak during critical phase is the hall mark Leading to 3rd space losses – peritoneal cavity – pleural cavity Variable in magnitude and exact timing

6. Pathogenesis of leak Infection with a virulent dengue virus Presence of antibodies that enhance dengue virus infection (ADE) Intense immune activation

7. Pathogenesis Rapidly elevated cytokines (TNF-a, IL-2, IL-6, IL-8, IL-10, IL-12, and IFN-g) Malfunction of vascular endothelial cells Plasma leakage from intra to extravascular space

8. Pathogenesis In severe DHF the loss of plasma is critical Patient becomes hypovolaemic Signs of circulatory compromise Progress to shock, organ failure, death

9. Pathogenesis Cytokine Storm Self limited Ends after 48 hours

10. Clinical Implications Extravascular fluid loss at variable rate that has to be matched ml for ml Lasting 48 hours Resorption of fluid during convalescent phase

11. Key Points Manage critical phase with appropriate volume – Don’t under transfuse – Don’t over transfuse Meticulous monitoring during critical phase to match rate of fluid infusion with rate of leak

12. Monitoring Parameters Clinical – Pulse Rate – Blood and Pulse Pressure – Capillary Refill Time – Urinary Output Lab – Hematocrit

13. Fluid Management Critical Phase

14. Amount of Fluid? Based on weight Adults – If less than 50kg use actual weight – If more take weight as 50 kg Paediatrics – Current OR Ideal body weight whichever is lower

15. Ideal Body Weight Weight for height using a growth chart Weight for age Formulae in emergency

16. Growth Charts

19. Formulae <1 year : Age (in Months)+ 9/2 1-7 years : (Age x 2)+ 8 >7 years : Age x 3 APLS : (Age in years + 4) x 2

20. Fluid Quota M + 5% = Maintenance + 5% of body weight Over 48 hours if patient presents in the beginning of critical phase (without shock) Over 24 hours for patients coming in shock

23. M + 5% - Adults Maintenance – 1st 10 kg – 1000 mls – 2nd 10 kg – 500 mls – Remaining 30kgs – 600 mls – Sum = 2100 mls 5% deficit – 50 x 50 = 2500 mls Total = 4600 mls

24. Child 22 kg Maintenance – 1000 + 500 + 40 = 1540 mls 5% Deficit – 50 x 22 = 1100 mls Total 2640 mls

25. Types of Fluid Crystalloids – 0.9% Saline – 5%Dextrose 0.9% Saline – 5% Dextrose ½ saline

27. Monitoring – Critical Phase Vital parameters - hourly Fluid balance chart - assess three hourly HCT - six hourly

28. Fluid Management in Dengue Shock Syndrome

29. Compensated Body compensates for fluid loss Tachycardia Pulse Pressure narrows Prolonged CRT Fall in urine output to 0.5 mls/kg/hr

30. Decompensated Pulse pressure narrows further leading to unrecordable pulse and BP Urine output falls less than 0.5 mls/kg/hour Supply to myocardium and brain compromised

31. Fluid Resuscitation Crystalloids – N Saline Colloids – Dextran 40 in saline – 6% Starch All boluses part of fluid quota

32. Indications for Colloid Failure of crystalloid boluses to normalize pulse /BP Development of shock – with fluid overload – amount of fluid exceeding M + 5% deficit 10 ml/kg over 1 hour

33. Colloids Dextran may sometimes interfere with grouping and cross matching 3 doses of Dextran 40 during a 24 hour 5 doses of 6% Starch during 24 hour Remain in circulation for much longer

36. Refractory Shock - ABCS Blood – packed cells – whole blood Bicarbonate Glucose Calcium

37. Monitoring During Shock 15 minute monitoring of vital signs HCT immediately before and after each fluid bolus and then at least two to four hourly

38. Key Points – Managing DHF Recognizing the start of critical phase of DHF Predicting the rate of leak which may vary from patient to patient and within the same patient Matching the rate of infusion to rate of leak Being cognizant of the end of critical phase

39. Key Points – Managing DSS Meticulous monitoring Switching appropriately from crystalloids to colloids Recognizing need for blood transfusion